Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02466659 · ClinicalTrials.gov registry record · NA

Controlled Intermittent Alternate Occlusion (CIAO) Therapy for Intermittent Exotropia

A NA study, sponsored by Indiana University.

Terminated
Registry status
NA
Development phase
8
Enrollment target

NCT02466659: Clinical Trial NA study, sponsored by Indiana University.

NCT02466659 is a NA study that was terminated before completion, run by Indiana University. The registered enrollment target is 8 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02466659, a NA study, was terminated before completion, sponsored by Indiana University.

TERMINATED
Registry status
NA
Development phase
8 participants
Enrollment target

Study Summary

To determine the effectiveness of alternate occlusion therapy for the treatment of IXT among patients aged 3 to \< 11 years old.

Primary Outcome

IXT control score: referring to the Pediatric eye disease investigator group (PEDIG). PEDIG scale of control for IXT 1-5 is defined as the following: 5 = Constant exotropia 4 = exotropia \> 50% of the 30-sec period before dissociation 3 = exotropia \< 50% of the 30-sec period before dissociation 2 = No exotropia unless dissociated, recovers in \> 5 sec 1 = No exotropia unless dissociated, recovers in 1-5 sec 0 = No exotropia unless dissociated, recovers in \< 1 sec (phoria) Not Applicable = N

Interventions

  • DEVICE CIAO therapy Amblyz glasses

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2015-02-01
Est. Completion 2016-12-01
Phase NA
Indiana University

890 total trials

Why NCT02466659 stopped before completion

NCT02466659 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 1 intervention - of which CIAO therapy Amblyz glasses is the first listed.

NCT02466659 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02466659 about?

NCT02466659 is a clinical study titled "Controlled Intermittent Alternate Occlusion (CIAO) Therapy for Intermittent Exotropia". To determine the effectiveness of alternate occlusion therapy for the treatment of IXT among patients aged 3 to \< 11 years old.

What is the current status of trial NCT02466659?

This trial is currently terminated. It is a NA study. The enrollment target is 8 participants. The study started on 2015-02-01. Estimated completion is 2016-12-01.

What interventions are being tested in trial NCT02466659?

The interventions under investigation include: CIAO therapy Amblyz glasses (DEVICE).

Who is sponsoring clinical trial NCT02466659?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02466659's enrollment target sits among peer trials

8 1976th of 2000 higher than 19 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02466659, the US trial registry maintained by the National Library of Medicine. NCT02466659 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.